Loading...
Loading...
EDSA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 27.3K |
| Gross Profit | -27.3K |
| Operating Expense | 2,410.6K |
| Operating I/L | -2,410.6K |
| Other Income/Expense | 77.0K |
| Interest Income | 85.7K |
| Pretax | -2,333.5K |
| Income Tax Expense | 0.8K |
| Net Income/Loss | -2,334.3K |
Edesa Biotech, Inc. is a biopharmaceutical company specializing in the acquisition, development, and commercialization of clinical-stage drugs for inflammatory and immune-related diseases with unmet medical needs. The company's lead product candidates include EB05, a monoclonal antibody in Phase 3 clinical study for treating acute respiratory distress syndrome in covid-19 patients, and EB01, a topical treatment in Phase 2B clinical study for chronic allergic contact dermatitis. Additionally, Edesa Biotech has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10, positioning the company at the forefront of innovative treatments for these conditions.
